PilotHealth
First-in-human CRISPR cuts bad cholesterol 52.5% at 12 months
Fifteen patients received one infusion in a Phase I trial of experimental CTX310.
Written by AI1 source1 min
Loading…
Diagnostics, prosthetics, vaccines, genomics: the medicine that adds years to a life.
Medicine that wins years of life: AI-assisted screening examining millions of patients, next-generation vaccines, genomics moving from sequencing to treatment, prosthetics and implants restoring lost abilities. The section follows completed clinical trials, market authorisations, hospital roll-outs — the moment a technology stops being a paper and becomes care.
The numbers rule: cohorts, detection rates, avoided mortality, costs. We gladly cover the health systems deploying at scale — India, Brazil, Southeast Asia — because frugal technologies often prove themselves there before arriving anywhere else. Every article rests on the trial, authorisation or study behind it, and cites them.
Fifteen patients received one infusion in a Phase I trial of experimental CTX310.
Participants had lost about 84% of their scalp hair before treatment began.
Six people with treatment-refractory disease received the therapy at Charité in Berlin.
The model used five early clinical variables to estimate conversion within one year.
The test uses an extra four microliters of blood and returns a result in 10–20 minutes.
The ACCESS trial studied 268 adults whose donors were mismatched at six of eight key HLA markers.
A UNC-led trial adapted Mediterranean-style eating to foods common in the Southeast.
The University of Surrey study identified three distinct five-year health trajectories among 12,701 UK heart-attack survivors.